Clinical Trials Browser

Completed × Prostatic Neoplasms, Castration-Resistant × pembrolizumab × Clear all

NCT03248570 2024-11-20

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Phase 2 Completed

26 enrolled 18 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant